Immuron Limited - Warrants (12/05/2022) Return on Equity

The latest ROE for IMRNW is -60.24%. That is below the Healthcare sector average of 11.15%. Investors often review this figure alongside Immuron Limited - Warrants (12/05/2022)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, IMRNW currently prints -60.24% for ROE, while the sector average sits near 11.15%. That is roughly 640.0% below the sector mean. Large gaps often invite a closer look at Immuron Limited - Warrants (12/05/2022)'s growth, margins, and balance sheet.

Return on Equity shows how effectively Immuron Limited - Warrants (12/05/2022) converts resources into returns. At -60.24%, IMRNW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting IMRNW's ROE (-60.24%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Immuron Limited - Warrants (12/05/2022)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.